R 568 hydrochloride
Cat. No. 3815
Chemical Name: 2-Chloro-N-[(1R)-1-(3-methoxyphenyl
Biological ActivityPositive allosteric modulator and allosteric agonist of the human calcium-sensing receptor (hCaSR). Exhibits calcimimetic activity. Has the ability to restore function to hCaSR mutants that cause familial hypocalciuric hypercalcemia (FHH) and neonatal severe hyperparathyroidism (NSHPT). Exerts a suppressive effect on parathyroid (PT) hormone secretion; inhibits PT cell proliferation in rats with renal insufficiency.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Wada et al (1997) The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. J.Clin.Invest. 100 2977. PMID: 9399943.
Fox et al (1999) NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J.Pharmacol.Exp.Ther. 290 473. PMID: 10411552.
Ying Lin Lu et al (2009) Effect of the calcimimetic R-568 [3-(2-chlorophenyl)-N-((1R)-1-(3-methoxyphenyl)ethyl)-1-propanamine] on correcting inactivating mutations in the human calcium-sensing receptor. J.Pharmacol.Exp.Ther. 331 775. PMID: 19759318.
If you know of a relevant citation for this product please let us know.
Keywords: R 568 hydrochloride, supplier, R568, hydrochloride, HCl, allosteric, modulators, and, allosteric, agonists, calcium-sensing, recptor, hCaSR
Find multiple products by catalog number
New Products in this Area
Potent Smo antagonistONO 8130
EP1 receptor antagonistTC-G 1008
Potent and selective GPR39 agonistRo 1138452 hydrochloride
Selective prostacyclin IP receptor antagonistJNJ 27141491
Potent and selective human CCR2 antagonistTY 52156
S1P3 receptor antagonistElinogrel
P2Y12 antagonistRactopamine hydrochloride
Trace amine 1 (TA1) receptor agonistTG 4-155
High affinity and selective EP2 receptor antagonist
September 5 - 8, 2015